Date: 2011-03-07
Type of information: R&D agreement
Compound: new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis
Company: AstraZeneca (UK) Galderma (Switzerland)
Therapeutic area: Autoimmune diseases - Dermatological diseases
Type agreement: R&D
Action mechanism:
Disease: dermatological conditions including psoriasis, acne and atopic dermatitis
Details: AstraZeneca and Galderma Pharma have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for millions of people worldwide.Under the terms of the agreement, Galderma will have exclusive access to a number of compounds from across AstraZeneca’s portfolio to develop in dermatological indications. Initial targets for collaboration have already been identified from disease areas as diverse as oncology, inflammation and central nervous system. These will be interrogated based on translational science and pre-clinical testing to determine the ones that will progress in the collaboration.
Financial terms: The financial terms of the five-year agreement were not disclosed.
Latest news:
